Equity Profile

OGN

Organon & Co.

Health CarePharmaceuticals$3.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and product offerings.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas. With a market cap of $4 billion, it plays a crucial role in addressing health care needs, particularly in women's health, which has gained increasing attention in recent years.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

In the last quarter, Organon reported an EPS of $0.71, which was lower than the expected $0.81, resulting in a negative surprise of nearly 13%. The stock reacted with a slight decline the following day.

Management Promises & Guidance

Focus on expanding the women's health portfolio.
Commitment to improving operational efficiencies.
Plans to enhance market penetration of existing products.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown a tendency to beat EPS estimates but has struggled with stock performance post-earnings. Investors will be watching closely for any signs of growth in revenue and profitability.

Bull Case

If Organon can demonstrate strong revenue growth and improve its EPS, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, especially in key areas like revenue, it could face further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this number will be critical in determining investor sentiment.

What is the revenue growth rate for the women's health segment?

This segment is vital for Organon's strategy, and strong growth here could indicate a successful market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for growth in the women's health segment, which could drive stronger-than-expected revenue.

Supporting Evidence

Historically, Organon has a 75% beat rate on EPS, suggesting potential for positive surprises.

Options pricing indicates a significant expected move, hinting at underlying volatility that could favor a rebound.

Key Risk

If the women's health revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can rebound from its recent earnings misses and show tangible growth in key areas.

Bull Confirmed If

A revenue growth rate of at least 10% in the women's health segment would confirm the bull case.

Bear Confirmed If

If EPS falls below $0.70, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests a potential stock increase of around 3% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors weigh future prospects.

Miss

A miss could lead to a decline of approximately 4% based on historical averages, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of the women's health product line.
2Any new partnerships or product launches that could drive growth.
3Management's outlook on operational efficiencies and cost management.
4Details on market expansion strategies and geographic growth.
5Insights into competitive pressures and how the company plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Organon & Co. is a pharmaceutical company focused on women's health and other therapeutic areas....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and product offerings.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

OGN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+7.95%

Avg Stock Reaction

-3.38%

Last Quarter Recap

Management Promises & Guidance

Focus on expanding the women's health portfolio.
Commitment to improving operational efficiencies.
Plans to enhance market penetration of existing products.

Expectations

Wall Street Expectations

Bull Case

If Organon can demonstrate strong revenue growth and improve its EPS, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations again, especially in key areas like revenue, it could face further stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for this quarter, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this number will be critical in determining investor sentiment.

What is the revenue growth rate for the women's health segment?

This segment is vital for Organon's strategy, and strong growth here could indicate a successful market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for growth in the women's health segment, which could drive stronger-than-expected revenue.

Supporting Evidence

Historically, Organon has a 75% beat rate on EPS, suggesting potential for positive surprises.

Options pricing indicates a significant expected move, hinting at underlying volatility that could favor a rebound.

Key Risk

If the women's health revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether the company can rebound from its recent earnings misses and show tangible growth in key areas.

Bull Confirmed If

A revenue growth rate of at least 10% in the women's health segment would confirm the bull case.

Bear Confirmed If

If EPS falls below $0.70, it would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.36%

Historical Avg

±10.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±21.4% while OGN has averaged ±10.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

95.4%

Calls (3K)P/C Ratio: 0.53Puts (52K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Organon beats expectations, history suggests a potential stock increase of around 3% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line but management's commentary is cautious, the stock may see muted movement as investors weigh future prospects.

Miss

A miss could lead to a decline of approximately 4% based on historical averages, reflecting ongoing concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of the women's health product line.
2Any new partnerships or product launches that could drive growth.
3Management's outlook on operational efficiencies and cost management.
4Details on market expansion strategies and geographic growth.
5Insights into competitive pressures and how the company plans to address them.